Stifel raises Ligand Pharma stock price target on XOMA acquisition

Ligand raised 2026 royalty revenue guidance by $25 million to $270 million-$310 million and lifted adjusted Core EPS guidance by $0.50 to $8.50-$9.50, alongside continued bullish analyst actions. The company is buying XOMA for $39 per share in cash, a $739 million transaction plus a contingent value right, which should double Ligand’s royalty portfolio and is expected to close in Q3 2026. Recent Q4 2025 results also beat estimates, with adjusted EPS of $2.02 vs. $1.49 expected and revenue of $59.7 million vs. $55.6 million.

Analysis

LGND is no longer just a royalty compounder; the XOMA deal converts it into a scaled duration asset with a more defensible cash-flow profile. That matters because the market tends to underwrite biotech royalty platforms as if they were linear growth stories, when the real value creation comes from lowering revenue volatility and extending the asset base through multiple approval cycles. The step-up in 2026 guidance should also compress the perceived leverage risk on the balance sheet, which can bring in a different buyer cohort: income-oriented healthcare allocators who typically avoid smaller-cap biotech names until cash coverage is visibly self-funding.

The second-order winner may be the broader royalty ecosystem rather than the obvious pharma beneficiaries. If LGND can finance an acquisition this size while still preserving deployment capacity, it raises the bar for smaller royalty aggregators and could force either consolidation or richer valuation marks across the group. Conversely, private royalty sellers and litigation-sensitive assets may become more competitively bid, since the market will now pay for portfolio breadth plus embedded optionality rather than just near-term cash yield.

The main risk is timing mismatch: the deal closes in 2026, while the stock is already pricing a lot of the pro forma uplift. That creates a window where any integration slippage, financing-cost surprise, or a single royalty asset disappointment can hit the multiple harder than the cash flow impact would justify. The contrarian angle is that the move may be more about de-risking than rerating; if investors start treating LGND like a bond proxy with biotech optionality, upside may slow while downside support improves, making it a better pullback buy than a chase at the high end of the range.

Key Decisions for Investors

• Stay long LGND, but prefer buying on a 5-8% pullback versus chasing here; the best risk/reward is if the stock resets while 2026 guidance remains intact.
• Sell near-dated upside against a core LGND long if options liquidity allows; the market is likely overpaying for immediate rerating before the 2026 close, so covered calls can monetize elevated expectations.
• Pair trade: long LGND / short a basket of smaller royalty names with weaker balance sheets and fewer late-stage assets over a 3-6 month horizon; LGND should command a quality premium if investors re-rate the platform for self-funding cash generation.
• Avoid adding exposure into the merger-close window unless financing spreads or credit conditions widen materially; the key risk is not thesis failure but multiple compression if the market questions acquisition accretion timing.
• If you want upside convexity, use call spreads in LGND rather than common; the catalyst path is real but stretched by the current price relative to the announced economics.